Autoantigen‐Dexamethasone Conjugate‐Loaded Liposomes Halt Arthritis Development in Mice
Advanced Healthcare Materials · 2024
DOI: 10.1002/adhm.202304238 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Naomi Benne und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, 3584 CL, The Netherlands. Hauptthemen laut MEDLINE: Liposomes, Dexamethasone, Autoantigens, Dendritic Cells. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ReumaNederland.
Abstract (Originalsprache)
There is no curative treatment for chronic auto‐inflammatory diseases including rheumatoid arthritis, and current treatments can induce off‐target side effects due to systemic immune suppression. This work has previously shown that dexamethasone‐pulsed tolerogenic dendritic cells loaded with the arthritis‐specific antigen human proteoglycan can suppress arthritis development in a proteoglycan‐induced arthritis mouse model. To circumvent ex vivo dendritic cell culture, and enhance antigen‐specific effects, drug delivery vehicles, such as liposomes, provide an interesting approach. Here, this work uses anionic 1,2‐distearoyl‐sn‐glycero‐3‐phosphoglycerol liposomes with enhanced loading of human proteoglycan‐dexamethasone conjugates by cationic lysine tetramer addition. Antigen‐pulsed tolerogenic dendritic cells induced by liposomal dexamethasone in vitro enhanced antigen‐specific regulatory T cells to a similar extent as dexamethasone‐induced tolerogenic dendritic cells. In an inflammatory adoptive transfer model, mice injected with antigen‐dexamethasone liposomes have significantly higher antigen‐specific type 1 regulatory T cells than mice injected with antigen only. The liposomes significantly inhibit the progression of arthritis compared to controls in preventative and therapeutic proteoglycan‐induced arthritis mouse models. This coincides with systemic tolerance induction and an increase in IL10 expression in the paws of mice. In conclusion, a single administration of autoantigen and dexamethasone‐loaded liposomes seems to be a promising antigen‐specific treatment strategy for arthritis in mice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, 3584 CL, The Netherlands.
- Utrecht Institute for Pharmaceutical Sciences, Department of Pharmaceutics, Faculty of Science, Utrecht University, Utrecht, 3584 CG, The Netherlands.
- Department of Materials Engineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan.
ORCID-Profile: Naomi Benne, Daniëlle Ter Braake, Deja Porenta, Chun Yin Jerry Lau, Enrico Mastrobattista, Femke Broere
Förderung
- ReumaNederland
Zitieren
APA
Benne, N., Ter Braake, D., Porenta, D., Lau, C. Y. J., Mastrobattista, E., & Broere, F. (2024). Autoantigen‐Dexamethasone Conjugate‐Loaded Liposomes Halt Arthritis Development in Mice. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202304238
Vancouver
Benne N, Ter Braake D, Porenta D, Lau CYJ, Mastrobattista E, Broere F. Autoantigen‐Dexamethasone Conjugate‐Loaded Liposomes Halt Arthritis Development in Mice. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202304238
BibTeX
@article{Benne2024,
author = {Benne, Naomi and Ter Braake, Daniëlle and Porenta, Deja and Lau, Chun Yin Jerry and Mastrobattista, Enrico and Broere, Femke},
title = {Autoantigen‐Dexamethasone Conjugate‐Loaded Liposomes Halt Arthritis Development in Mice},
journal = {Advanced Healthcare Materials},
year = {2024},
doi = {10.1002/adhm.202304238}
}
EUVIMED